Advertisement

Author: Elizabeth Gregerson

Five cardiology and one radiology advocacy groups have called on Elevance Health to review its latest coverage guidelines for the treatment of varicose veins.  The insurer’s guidelines, published April 16, categorize the use of endovenous cyanoacrylate closure during varicose vein…

In June 2024, Children’s National Hospital appointed Wayne Franklin, MD, as senior vice president of its Heart Center. Just one year into his tenure, the hospital’s cardiac team achieved a milestone: performing the world’s first partial heart transplant to replace…

In June 2024, Children’s National Hospital appointed Wayne Franklin, MD, as senior vice president of its Heart Center. Just one year into his tenure, the hospital’s cardiac team achieved a milestone: performing the world’s first partial heart transplant to replace…

An automated AI system accurately performed echocardiogram interpretation with a median normalized mean absolute error of 0.13, according to a study published June 23 in JAMA.  Researchers trained the system, called PanEcho, on echocardiogram data from transthoracic echocardiographs performed at…

Advertisement

An automated AI system accurately performed echocardiogram interpretation with a median normalized mean absolute error of 0.13, according to a study published June 23 in JAMA.  Researchers trained the system, called PanEcho, on echocardiogram data from transthoracic echocardiographs performed at…

Tacoma, Wash.-based MultiCare Health System has named Hilary Whittington as CEO of the Pulse Heart Institute. Ms. Whittington has been the heart institute’s CFO since 2020, according to a June 23 news release from MultiCare. She began serving as CFO…

Cass Wheeler, former CEO of the American Heart Association, has died. He served as the organization’s CEO from 1998 to 2008. During his time as CEO, Mr. Wheeler led the unification of the American Heart Association’s state and metropolitan chapters…

The American College of Cardiology has recommended that physicians embrace weight loss medications, such as semaglutide and tirzepatide, as first-line treatment options for patients at risk of cardiovascular disease.  The recommendations are part of an expert consensus published June 20…

Advertisement